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Introduction: Approximately 100 million confirmed infections and 20,000 deaths are caused by Dengue virus (DENV)
outbreaks annually. Global warming and rapid dispersal have resulted in DENV epidemics in formally non-endemic
regions. Currently no consistently effective preventive measures for DENV exist, prompting development of transgenic
and paratransgenic vector control approaches. Production of transgenic mosquitoes refractory for virus infection and/
or transmission is contingent upon defining antiviral genes that have low probability for allowing escape mutations,
and are equally effective against multiple serotypes. Previously we demonstrated the effectiveness of an anti-viral group
I intron targeting U143 of the DENV genome in mediating trans-splicing and expression of a marker gene with the
capsid coding domain. In this report we examine the effectiveness of coupling expression of ΔN Bax to trans-splicing
U143 intron activity as a means of suppressing DENV infection of mosquito cells.
Results: Targeting the conserved DENV circularization sequence (CS) by U143 intron trans-splicing activity appends a
3’ exon RNA encoding ΔN Bax to the capsid coding region of the genomic RNA, resulting in a chimeric protein that
induces premature cell death upon infection. TCID50-IFA analyses demonstrate an enhancement of DENV suppression
for all DENV serotypes tested over the identical group I intron coupled with the non-apoptotic inducing firefly luciferase
as the 3’ exon. These cumulative results confirm the increased effectiveness of this αDENV-U143-ΔN Bax group I intron
as a sequence specific antiviral that should be useful for suppression of DENV in transgenic mosquitoes. Annexin V
staining, caspase 3 assays, and DNA ladder observations confirm DCA-ΔN Bax fusion protein expression induces
apoptotic cell death.
Conclusion: This report confirms the relative effectiveness of an anti-DENV group I intron coupled to an
apoptosis-inducing ΔN Bax 3’ exon that trans-splices conserved sequences of the 5’ CS region of all DENV serotypes
and induces apoptotic cell death upon infection. Our results confirm coupling the targeted ribozyme capabilities of
the group I intron with the generation of an apoptosis-inducing transcript increases the effectiveness of infection
suppression, improving the prospects of this unique approach as a means of inducing transgenic refractoriness in
mosquitoes for all serotypes of this important disease.
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Dengue virus (family Flaviviridae) is maintained in a cycle
between humans and the widely distributed Aedes aegypti
mosquitoes [1,2]. Approximately 100 million infections
and 20,000 deaths each year are attributed to mosquito-
borne DENV infections. An additional 2.5 billion people
worldwide remain at risk making this virus one of the
most critically important pathogens in the world [3].
However, a more severe global scenario of dengue virus
infections has been presented. Bhatt et al. estimated using
cartographic models that there are as much as 390 million
dengue virus infections annually [4]. The reason for the
discrepancy is that approximately 290 million are asymp-
tomatic or mild ambulatory infections that have no need
for clinical management and are unrecorded. Asymptom-
atic infections affect precise determination of economic
impact, elucidation of population dynamics of dengue
viruses [4], and establishment of future vaccination
programs.
The WHO has reported outbreaks in Key West, Florida
in 2009 and 2010, Puerto Rico in 2010, and Miami-Dade
County and Pakistan in 2011 [5-8]. Most recently, the
WHO reported dengue outbreaks in 2012 on the Madeira
Islands of Portugal [9,10] resulting in over 2000 cases,
with imported cases detected in 10 other countries in
Europe [9,10]. In 2013, dengue cases were detected in
Florida (United States of America) [9]. Dengue continues
to be a major burden in several South American countries,
most notably Brazil, Honduras, Costa Rica and Mexico
[9,11-14]. In Asia, an increase in cases were reported in
Singapore after a lapse of several years, and outbreaks
have been reported in Laos, and the Chinese province of
Yunnan [9]. In 2014, after an absence of over 10 years data
indicates increases in the number of dengue cases in the
Pacific countries of the Cook Islands, Malaysia, Fiji and
Vanuatu [9].
Infection with one of four orthologous, but antigenically
distinct DENV serotypes (designated DENV 1 through 4)
can result in dengue fever (DF) or dengue hemorrhagic
fever (DHF) [3]. DF and DHF are endemic to tropical and
subtropical regions of the world, but global changes in cli-
mate, rapid dispersal of virus due to travel and commerce,
and increased human migration to non-tropical regions
has resulted in epidemic DENV outbreaks in areas that
are non-endemic for these viruses [1,2]. There are cur-
rently no consistently effective preventive control mea-
sures or approved tetravalent vaccines to combat DENV.
Population replacement of vector competent mosqui-
toes with transgenic mosquitoes that are refractory for
virus infection and/or transmission has been proposed as
a potentially long lasting, cost effective, and safe control
measure for interrupting the dengue disease transmission
cycle [15,16]. The success of this approach relies, in large
part, upon defining DENV suppressive approaches thatlimit or prevent the evolution of escape mutants, and are
effective against multiple strains and serotypes.
Our lab has been surveying ribozymes as DENV sup-
pressive agents for use in generating refractory transgenic
mosquitoes. In a previous report we examined the effec-
tiveness of hammerhead ribozymes in suppressing DENV
infection in retrovirus transduced mosquito cells [17]. We
identified several hammerhead ribozymes that were ef-
fective in significantly reducing DENV serotype 2 New
Guinea strain (DENV2-NGC) infection of Ae. albopictus
C6/36 cells. However, the inability to target sequences that
are conserved among all DENV serotypes by this method
necessitated exploration of ribozymes that have an in-
creased potential for broader specificity. As an alternative
we demonstrated the utility of a group I intron trans-spli-
cing strategy to target circularization sequences (CS) that
are highly conserved among all DENV genomes [18].
Trans-splicing group I introns provide a versatile tool
for repairing erroneous or unwanted RNA [19-29], and
have been used for a number of applications, including
repair of defective α-globin mRNA [20], renovation of
wild-type p53 function [30], re-establishment of canine
skeletal muscle chloride channel function [31], and in-
duction of p16 activity in a pancreatic cell line [22].
More applicable to our research are examples of trans-
splicing group I introns targeting the HIV-1 tat sequence
[32], cucumber mosaic virus coat protein mRNAs [19],
and the hepatitis C virus internal ribosome entry site
(HCV-IRES; [33]).
Any method of inhibition of DENV infection by inter-
action with the RNA genome must be designed to target
highly conserved sequences [34-36]. The 5’ and the two 3’
cyclization sequences (5’ CS, CS1, and CS2) of the DENV
genome are the most invariant segments, and are essential
for formation of the panhandle structure required for gen-
ome replication [37,38]. The 5’ CS is located downstream
of the polyprotein start codon, well within the ORF of the
Capsid (CA) protein sequence. The stringency of tolerable
mutations in this sequence among DENV may be in-
creased, in part, by the need for the virus to conserve a
functional CA protein. Moreover, all mosquito-borne
flaviviruses share an 8bp stretch of nucleotides within this
5’ CS sequence [39].
We previously demonstrated the effectiveness of group
I introns targeting sequences in the DENV 5’ CS [18].
While these group I introns demonstrated the capability
to splice within this conserved region, the use of these
molecules as simple catalytic genome destroying agents
necessarily requires levels of expression that match or
exceed those for the generation of viral genomes in
infected cells. Escape mutants may emerge in the event
virus replication exceeds group I intron catalytic sup-
pression. As a result, expression of anti-viral group I in-
trons alone in cells may not be the ideal method for
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while suppressing DENV expression. Coupling the splicing
activity of the group I intron to a death-upon-infection
strategy could provide an added level of insurance against
the emergence of escape mutants. Designing anti-DENV
group I introns coupled with apoptosis-inducing genes as
the 3’ exons to induce cell death upon infection with
DENV would increase the effectiveness of infection sup-
pression and could diminish the probability of escape mu-
tant emergence.
This report confirms the relative effectiveness of an
anti-DENV group I intron coupled to an apoptosis-indu-
cing ΔN Bax 3’ exon that trans-splices conserved se-
quences of the 5’ CS region of all DENV serotypes and
induces apoptotic cell death upon infection. The proapop-
totic ΔN Bax was chosen as the 3’ exon because of its abil-
ity to irreversibly initiate apoptosis more rapidly than Bax
[40] due to deletion of the Bax BH-3 domain that facili-
tates protein-protein interactions between Bax and Bcl-2
or other anti-apoptotic regulators. We demonstrate this
introns’ antiviral and apoptosis-inducing activity in trans-
formed mosquito cell cultures challenged with infectious
DENV of all four serotypes. Our results confirm that
coupling the targeted ribozyme capabilities of the group I
intron with the generation of an apoptosis-inducing tran-
script increases the effectiveness of infection suppression
and improves the prospects of this unique approach as a
means of inducing transgenic refractoriness in mosquitoes
for all serotypes of this important disease.Figure 1 Anti-DENV group I intron targeting and trans-splicing DENV
targeting the DENV genome and the associated trans-splicing reaction. The
serotypes [18]. The uracil at position 143, located within the 5’ CS domain,
RNAs are indicated. IGS = Internal guide sequence, EGS = external guide seqResults
Basic trans-splicing mechanism of group I introns
The trans-splicing mechanism of the Tetrahymena thermo-
phila group I intron is characterized by two independent
transesterification reactions ([41]; Figure 1). Ribozyme and
target RNAs base pair to form the P1 and extended anti-
sense helices with the subsequent guanosine-mediated
transesterification resulting in cleavage of the target DENV
RNA (Step 1). The external guide sequence (EGS) provides
additional stability for the trans-splicing reaction through
Watson-Crick base pairing with nucleotides downstream
from the reactive uracil on the target RNA. The distal por-
tion of helix P1 is displaced by sequences from the 3’ exon
(ΔN Bax) to form helix P10 (Step 2). This allows the se-
cond transesterification to proceed, resulting in ligation of
the DENV capsid and ΔN Bax (Step 3). The end result is a
new RNA molecule that, if appropriately configured, can
be translated into a fusion protein sequence.
Construction of the αDENV-U143-ΔN Bax vectors
In a previous report we describe the construction and
trans-splicing activity of a U143 intron that effectively
trans-splices all known DENV genomes by targeting the
uracil at position 143 within the 5’ CS [18]. This trans-spli-
cing anti-DENV group I intron, designated αDENV-U143,
includes a 9 nucleotide EGS that base pairs to sequences
conserved among all DENV genomes to improve the tar-
geting capability of the intron and to minimize potential
off-target splicing interactions. An internal guide sequencetargets. Illustration of the anti-DENV group I intron, αDENV-U143,
targeted 5’ CS domain of the DENV genome is conserved among all
is targeted for cleavage. Ribozyme and target DENV genomic (blue)
uence, CS = cyclization sequence.
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wobble base pair with the targeted uracil. A single variable
base at nucleotide 152 is positioned within a non-homolo-
gous bulge loop (BL) structure that separates the IGS and
EGS, and therefore does not influence the targeting of the
intron [18]. This BL structure allows the formation of
the P10 helix which increases the catalytic efficiency of the
intron [42]. Excluding the wobble base with the uracil at
nucleotide position 143 which is required for proper cleav-
age [43-46], 17 bases of this intron interact directly with the
intended target sequence.
In this study we modified αDENV-U143 by incorpora-
ting a ΔN Bax coding sequence as the 3′ exon (Figure 2).
The ΔN Bax sequence corresponds to amino acids 112–
192 of the Bax protein sequence, and induces cell death in
A549 and NCI-H1299 cell lines more efficiently than tBax
through a caspase-independent mechanism [40]. To
insure that this potent apoptosis inducer was not ex-
pressed independently of splicing from the αDENV-U143-
ΔN Bax intron we inserted a UAA stop codon into the
P9.0 helix of the group I intron immediately upstream of
the UCG splice donor (Figure 2).
We also constructed an inactive negative control group
I intron, αDENV-ΔU143, by removing the entire catalytic
core, domains P4 through P6, of αDENV-U143 [18] as
described in Methods. The removal of domains P4
through P6 was necessary since a previously described
ΔP5abc intron had demonstrated residual trans-splicing
activity [47]. We further modified the αDENV-U143-ΔN
Bax by attaching a Drosophila C Virus (DCV) IRES-
dependent mCherry fluorescent marker gene downstream
of the ΔN Bax 3’ exon. The DCV dicistrovirus IRES se-
quence previously yielded high levels of expression Ae.Figure 2 Schematic of the group I (trans-splicing) intron
expression cassette. Each trans-splicing αDENV-U143 group I intron
was tagged downstream of the ΔN Bax 3’ exon with the mCherry
fluorescent marker gene expressed from the Drosophila C virus
(DCV) IRES sequence. Expression of this construct was driven by the
Drosophila melanogaster Actin 5c promoter (A5c). This bi-cistronic
configuration allowed monitoring for the presence and expression
of the anti-DENV group I intron constructs within cell cultures.
A5c = Drosophila Actin 5c promoter, EGS = External guide sequence,
IGS = Internal guide sequence, TSD = Trans-splicing domain,
ΔN Bax = pro-apoptotic 3’ exon, IRES = Internal ribosome entry site.aegypti mosquito cells [48]. This bi-cistronic configuration
allowed monitoring for the presence and expression of the
anti-DENV group I intron constructs within mosquito cell
cultures. The entire construct was designed to be ex-
pressed in mosquito cells using the Drosophila melanoga-
ster Actin 5c promoter (A5c).
Expression of ΔN Bax initiates apoptosis
The αDENV-U143-ΔN Bax group I intron cleaves within
19 amino acids of the terminus of the DENV polyprotein
open reading frame at U143 and appends the ΔN Bax 3’
intron to the DENV CA protein coding sequence (DCA).
We analyzed the relative effectiveness of expression of this
DCA-ΔN Bax fusion protein from this predicted RNA
configuration, and verified its capabilities as an inducer of
apoptosis in C6/36 cells. The copper sulfate-inducible
metallothienine promoter (pMT) was employed to control
expression of transcripts encoding the apoptosis negative
control DCA, the predicted DCA-ΔN Bax fusion protein,
the unaltered ΔN Bax protein, or a DCA-FMDV2A-ΔN
Bax transcript that was predicted to independently express
ΔN Bax from DCA. At 48 hours post-induction proteins
were harvested and analyzed by western blot with anti-
Bax antibody as described in Methods. No protein bands
were evident from the DCA lysates (Figure 3A) while
the DCA-ΔN Bax fusion protein (12.1 kb) and ΔN Bax
(9.6 kb) were produced at similar levels from their res-
pective expression constructs, demonstrating that the 19
amino acid DCA extension of the N-terminus of ΔN Bax
has no observable effect on the efficiency of expression of
the protein product.
Physiological determinants of apoptosis such as cellu-
lar shrinkage and detachment [49] may be conveniently
assayed by amido black staining [50,51]. To confirm re-
tention of apoptotic activity for the DCA-ΔN Bax fusion,
we performed amido black assays on C6/36 cells co-
transfected with the pMT-EYFP induction marker plas-
mid and each of the inducible DCA, ΔN Bax, DCA-ΔN
Bax, and DCA-FMDV2A-ΔN Bax expression plasmids
(Figure 3B). Cells expressing the DCA negative control
displayed a significant difference in cell detachment at
each time point compared to cells expressing some form
of ΔN Bax. No significant differences were observed
among the values obtained for the pMT-ΔN Bax or
pMT-DCA-ΔN Bax transfected cells at any time point.
While this assay was not considered definitive for quan-
titating apoptosis activity, the results were consistent
with the induction of an apoptotic response by the
DCA-ΔN Bax fusion protein.
The αDENV-U143-ΔN Bax intron construct effectively
targets all DENV serotypes
We examined the effectiveness of αDENV-U143-ΔN Bax
to target all DENV serotypes in transformed Ae. albopictus
Figure 3 Assessment of ΔN Bax expression and proapoptotic
activity. A. Western blots were performed as described in Methods.
DCA, DCA-ΔN Bax, FMDV2A-ΔN Bax, and ΔN Bax probed with
Bax C-terminal specific antibody. The bottom bands are corresponding
actin loading controls. B. The relative amount of amido black recovered
from each well is inversely proportional to the extent of apoptosis.
The DCA wells were set to a value of 1 for each time point and the
readings for all other wells at each time point were adjusted by the
corresponding ratio [50]. Measurements were recorded in triplicate for
each time point. Statistical analysis was performed using ANOVA test
with Tukey post test. Differences were statistically significant with
p values less than 0.05.
Carter et al. Virology Journal 2014, 11:111 Page 5 of 18
http://www.virologyj.com/content/11/1/111C6/36 cells (Figure. 4A through D). Intron-expressing cell
lines were generated by co-transfection of C6/36 cells with
a hygromycin selectable marker plasmid and A5c pro-
moter plasmids expressing either the inactive αDENV-
ΔU143-ΔN Bax or the trans-splicing αDENV-U143-ΔN
Bax introns that were each linked and unlinked to a DCV-
IRES/ mCherry. Following selection, the transformed
C6/36 cells were seeded at a density of 2.0 × 105 cells/cm2per T25 flask, and were challenged with each of the four
DENV serotypes at 0.1 MOI.
Total cellular RNA isolated at 96 hours post-infection
was assessed for αDENV-U143-ΔN Bax activity by RT-
PCR amplification of trans-spliced products and the iden-
tity of these product bands were confirmed by sequencing.
Spliced products of approximately 250 bp with appro-
priate junction sequences were observed as a result of
targeting the DENV genome, regardless of serotype
(Figure 4). Targeting and cleavage occurred whether the
αDENV-U143-ΔN Bax configuration was linked or un-
linked to a DCV-IRES/mCherry extension. As expected
the αDENV-ΔU143 inactive anti-DENV group I intron
did not catalyze a trans-splicing reaction.
Expression of αDENV-U143-ΔN Bax introns from the A5c
promoter appends 56 nt of RNA sequence to the
5’ terminus
Previous analysis of αDENV group I introns using the
A5c promoter [18] demonstrated targeting and cleavage
effectiveness against both synthetic targets and viral ge-
nomes. Of concern was the possibility that the catalytic
activity might be influenced by variability in the length
of the 5’ terminus of the expressed transcript, effectively
causing varying degrees of interference with the proper
alignment between the external or internal guide se-
quences and the target genome.
The putative transcription start site (TSS) of the A5c
promoter was previously reported as being at 56 nucleo-
tides upstream of the 5’terminus of our αDENV-U143-ΔN
Bax group I intron sequence (Additional file 1: Figure S1A;
[52]). We determined the precise TSS of our anti-DENV
group I intron transcripts using 5’-RLM-RACE analysis
(RNA Ligase Mediated-Rapid Amplification of cDNA
Ends) on the expressed αDENV-U143-ΔN Bax intron.
Since all expression plasmids possessed the same promoter
and targeting sequences (i.e. EGS and IGS) there was no
need to perform this assay on all constructs. Gel elec-
trophoresis of RT-PCR products resulted in a distinct sin-
gle product band of approximately 250 bases (Additional
file 1: Figure S1B), as expected for a 56 nt 5’ extension,
indicating a homogeneous transcript length and TSS
(Additional file 1: Figure S1C).
Comparative CPE assays
DENV infection of C6/36 cells causes decreased cell pro-
liferation and a distinctive syncytium-inducing cytopathic
effect (CPE; [53,54]) mediated by cell surface expression
of the DENV envelope protein (DENV-E). If expression of
the αDENV-U143-ΔN Bax construct renders mosquito
cells refractory to DENV replication, absence of substan-
tial CPE should be evident.
CPE was most noticeable upon DENV infection of
C6/36 cells in the absence of the active U143-ΔN Bax,
Figure 4 αDENV-U143–ΔN Bax constructs effectively target all DENV serotypes A). Ae. albopictus C6/36 cells were transformed with
trans-splicing (αDENV-U143) or inactive (αDENV-ΔU143) group I intron vector constructs and maintained under hygromycin selection. U143-ΔN
Bax refers to the αDENV-U143 trans-splicing group I intron possessing the pro-apoptotic ΔN Bax as the 3’ exon. ΔU143-ΔN Bax refers to the
anti-DENV group I intron (αDENV-ΔU143) possessing the inactive deletion mutation of the trans-splicing domain that is linked to the ΔN Bax 3’
exon. The deletion mutation of the trans-splicing domain is designed to knock out trans-splicing function, providing a negative control [81]. At
15 hours post plating 5x106 cells were infected with A. DENV-1, B. DENV-2, C. DENV-3, D. DENV-4, each at MOI 0.1, and analyzed for the presence
of splice product 96 hours p.i. by RT-PCR with heterologous primers. A PCR amplification product derived from a separately constructed spliced
sequence control (DNA + Ctrl, see Methods) and a DNA ladder (L) are provided as size standards for each gel. U143-ΔN Bax-D and ΔU143-ΔN
Bax-D refer to the active and inactive intron-ΔN Bax constructs respectively that are linked to the DCV –IRES/mCherry configuration as shown
in Figure 2. Control RT-PCR experiments were performed with primers for actin to confirm similar RNA loading. Heterolgous primers to the
intron- ΔN Bax segment of the construct were used to confirm the presence of our anti-DENV introns. Arrows indicate the predicted size of the
principle splice products resulting from intron activity. The identity of spliced products was confirmed by sequencing.
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tron, αDENV-ΔU143-ΔN Bax (Figure 5). Infection of
C6/36 cells expressing the αDENV-U143-firefly lucifer-
ase (FL) group I intron induced significantly less CPE
than either untransformed or αDENV-ΔU143-ΔN Bax
transformed cells, demonstrating that expression of an
active group I intron is able to suppress DENV infection
regardless of the 3’ exon used. In contrast, cells express-
ing the αDENV-U143-ΔN Bax construct, whether linked
with a DCV-IRES/mCherry configuration or not, had no
detectable CPE following DENV infection. Incorporation
of the 3’ ΔN Bax exon controlled infection of the cell
cultures better than the expressed αDENV-U143 group I
intron alone, and suggested an improved effectiveness
with the apoptosis induction.
As expected, CPE was not evident in the absence of
DENV infection, but was observed following infection of
control C6/36 cells transformed with an A5c-promoted
mCherry plasmid. The latter control established that ab-
sence of CPE following DENV infection of αDENV-U143-FL or αDENV-U143-ΔN Bax intron transformed
cells was not attributable to hygromycin-mediated inhi-
bition of DENV replication.
Quantitative assessment of the relative effectiveness of
ΔN Bax as the 3’ exon
By observing suppression of CPE in C6/36 cells trans-
formed with αDENV-U143 group I introns having either
ΔN Bax or FL 3’ exons we qualitatively validated the
effectiveness of each intron as a transgenic suppressive
molecule. However, we expected that expression of a
DCA-ΔN Bax fusion product following DENV targeting
αDENV-U143- ΔN Bax would enhance the suppressive
effect over the similar αDENV-U143-FL group I intron
expressing the non-apoptotic DCA-FL fusion product.
The levels of virus produced from cultures of C6/36 cells
stably expressing either αDENV-U143-FL or αDENV-
U143-ΔN Bax were determined using TCID50-immuno-
fluorescence antibody assays following challenge with
0.1 MOI of each DENV serotype indicated (Figure 6;
Figure 5 CPE following DENV infection of group I intron transformed C6/36 cells. C6/36 cells were transformed with the anti-DENV group I
introns or mCherry expression plasmids, and challenged with DENV (MOI 0.1). Micrographs were taken at 6 dpi using an inverted phase microscope at
20× magnification. Representative infected cell cultures are shown. Cultures expressing functional αDENV-U143-ΔN Bax intron constructs exhibited no
CPE while some degree of cytopathology was observed for αDENV -U143-FL and the negative control αDENV -ΔU143-ΔN Bax. αDENV-U143-ΔN Bax-D
refers to the active intron-ΔN Bax construct that is linked to the DCV-IRES/mCherry configuration as shown in Figure 2.
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Bax consistently exhibited a large reduction of virus titer,
as much as 5 logs, in comparison to the untransformed in-
fection controls. Moreover, cultures transformed with
αDENV-U143- ΔN Bax exhibited approximately 2.5 logs
greater suppression than those transformed with αDENV-
U143-FL (Figure 6), confirming enhancement of DENV
suppression with ΔN Bax as the 3’ exon. Suppression of
virus replication is evident regardless of DENV serotype
targeted, or whether the DCV-IRES/mCherry configu-
ration is present in the anti-DENV constructs. Minor de-
creases in viral titers observed for cells stably expressing
the inactive anti-DENV group I intron ΔU143 or the con-
stitutively expressed mCherry control construct may be
attributed to interference from residual hygromycin [55].
Expression of the αDENV-U143-ΔN intron in clonal cell
populations leads to full suppression of DENV replication
While we were able to verify effective targeting and sup-
pression of DENV in transformed hygromycin-selectedC6/36 cells expressing our αDENV-U143 group I introns,
antibiotic selection alone was not capable of eliminating all
non-transformed cells resulting in some DENV infection in
the cultures. We expected that cloned cell populations
expressing αDENV-U143-ΔN Bax and αDENV-U143-
FL would demonstrate significantly improved DENV
suppression.
αDENV-U143-ΔN Bax and αDENV-U143-FL cell clones
were established using limited dilution (Methods), chal-
lenged with DENV-2 NGC (MOI = 0.1), and analyzed for
infectivity by fluorescence microscopy (Figure 7A and
Additional file 2: Figure S2). All but one of the 12
αDENV-U143-ΔN Bax clones analyzed (C-11) displayed
effective suppression of DENV-2 as opposed to 5 out of
12 for the αDENV-U143-FL transformed clones, clearly
demonstrating an enhancing effect associated with inclu-
ding the proapoptotic ΔN Bax gene as a 3’ exon. These
results illustrate the capabilities of this approach as a
means of achieving complete suppression of viral infection
when αDENV-U143-ΔN Bax is expressed in all cells.
Figure 6 U143–ΔN Bax constructs effectively suppresses DENV in transformed mosquito cells. C6/36 cells transformed with anti-DENV group
I introns were challenged with the DENV serotypes 1 through 4 (MOI 0.01). At 4 dpi supernatants were collected and viral titers were determined by
TCID50-IFA as described in [17]. Suppression of DENV replication is determined through detection of the cell surface expressed DENV E protein. Only in
mosquito cells expressing a functional αDENV-U143-ΔN Bax construct were suppression of DENV evident. Suppression of viral replication occurred with all
serotypes tested, and was increased when FL was replaced by αDENV-U143-ΔN Bax or αDENV-U143-ΔN Bax-D as the 3-exon. U143-ΔN Bax-D refers to the
active αDENV-U143-ΔN Bax construct that is linked to the Drosophila C virus DCV IRES/mCherry configuration as shown in Figure 2. I-Wt = infected naïve
C6/36 cells. I-mCh =DENV infected C6/36 cells transformed with a construct constitutively expressing the mCherry fluorescent marker. U = uninfected naïve
C6/36 cells. ΔN B=ΔN Bax.
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confirmed our antibody assay results (see Figure 7A).
RT-PCR of cell supernatants harvested from DENV in-
fected cells at 4 dpi demonstrated that cloned cell popula-
tions expressing αDENV-U143-ΔN Bax (except C-11) are
unable to support DENV replication as evidenced by the
inability to detect DENV RNA.
To assess the effectiveness of these clones in suppressing
all DENV serotypes we performed TCID50-IFA [17,18] at
four days following infections of each αDENV-U143-FL
and αDENV-U143-ΔN Bax cell clone with each DENV
serotype (MOI = 0.01). As expected, quantitation of DENV
replication suppression mirrored the fluorescence mi-
croscopy and RT-PCR assays for all DENV serotypes
(Figure 7C). Total suppression of all DENV serotypes was
observed in 11 of the 12 αDENV-U143-ΔN Bax clones as
compared to only 5 of 12 for the αDENV-U143-FL cloned
populations, providing additional confirmation of an
enhancement of DENV suppression with proapoptotic ΔN
Bax as the 3’ exon over FL. Suppression of DENV replica-
tion is evident regardless of serotype targeted.
The lone C6/36 clonal cell line stably expressing
αDENV-U143-ΔN Bax that did not display full DENV
suppression (C-11) still displayed a significant reduction
in DENV titer, approximately 5 logs, in comparison to the
infection control. This likely reflects that this was not a
purely clonal population of cells or that the αDENV-
U143-ΔN Bax was poorly expressed in these cells. Weattribute the minor decreases in viral titers observed for
cells stably expressing the inactive αDENV-ΔU143 or the
constitutively expressed mCherry control construct to
interference from residual hygromycin [55].
ΑDENV-U143-ΔN Bax initiates apoptosis upon dengue
virus infection
While infection assays clearly demonstrated suppression
of DENV infection and generation of the appropriate
splice products, we needed to verify the improved effec-
tiveness of the ΔN Bax 3’ exon resulted from induction of
apoptosis in DENV infected cells expressing the αDENV-
U143-ΔN Bax. We chose three assays, annexin V staining
(Figure 8A), caspase 3 expression (Figure 8B), and DNA
ladder production (Figure 9 and Additional file 3: Figure
S3) to verify unambiguously the induction of all stages of
apoptotic cell death as a response to DENV infection of
cells expressing the αDENV-U143-ΔN Bax.
Annexin V-FITC assays [51,56,57] were performed to
directly demonstrate the ability of the expressed DCA-ΔN
Bax fusion proteins to initiate apoptosis. Following DENV
challenge at 0.1 MOI with each serotype, 1×106 trans-
formed C6/36 clonal cells stably expressing αDENV-
U143-ΔN Bax constructs were washed and stained with
FITC-conjugated annexin V at 48 hours post infection and
analyzed on a 96 well microtiter plate as described in
Methods (Figure 8A). As a control, C6/36 cell lines stably
expressing αDENV-U143-ΔN Bax constructs in the absence
Figure 7 (See legend on next page.)
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Figure 7 αDENV-U143–ΔN Bax constructs effectively suppress DENV in clonal populations of transformed mosquito cells. A. Clonal cell
populations (labeled C-1 through C-11) were challenged with DENV-2 NGC (MOI 0.01). At 4 dpi cell supernatants were collected and saved for
RT-PCR analysis. Following DENV-2 E protein antigen staining with antibody, micrographs were taken using the A1-R confocal microscope (Nikon).
The figure displayed is an example of what is shown in Additional file 1: Figure S1. Green glowing cells, indicative of positive DENV E-2 staining,
were observed only in cells actively replicating DENV. B. RT-PCR analysis of αDENV-U143-FL and αDENV-U143-ΔN Bax clonal cell populations.
Supernatants from cell populations were collected prior to antibody staining of cells. RNAs were extracted as described in Methods. RT-PCR
amplification was performed with primers to DCA and amplification products were separated on a 2% TAE agarose gel. Control RT-PCR experiments
were performed with primers to actin to confirm RNA loading. Heterolgous primers to the intron- ΔN Bax segment of the construct were performed
to confirm the presence of our anti-DENV effectors. The approximate sizes (in bases) of the RT-PCR products are indicated. Representative infected
cell cultures are shown. C. αDENV-U143–ΔN Bax is capable of full DENV suppression. C6/36 clonal cell populations (designated C-1 through C-12)
expressing αDENV-U13-FL or αDENV-U143–ΔN Bax were infected with each of the four DENV serotypes and TCID50-IFA analysis was performed as
described in Methods. I-Wt = infected naïve C6/36 cells. I-mCh = DENV infected C6/36 cells transformed with a construct constitutively expressing the
mCherry fluorescent marker. U = uninfected naïve C6/36 cells.
Figure 8 Annexin V and Caspase 3 assays validate apoptosis by αDENV-ΔU143-ΔN Bax activation. A. Promotion of the initial stages of
apoptosis by αDENV-ΔU143-ΔN Bax activation. Clonal Aedes albopictus C6/36 cells transformed with αDENV -U143-FL, αDENV -ΔU143-ΔN Bax or αDENV
-U143-ΔN Bax were challenged with either one of the four DENV serotypes. 1x106 cells were stained with FITC conjugated Annexin V at 48 hpi (with
DENV) and analyzed in a 96-well microtiter plate format per the manufacturer’s instructions (Cayman Chemical Company). Uninfected clonal and wild
type C6/36 cells were also assayed as an additional negative control. Assays were performed in triplicate. Error bars indicate standard deviation of three
independent experiments. B. Caspase-3 activation confirms the induction of apoptosis by the activation of Dual Targeting Intron Constructs. Clonal
Aedes albopictus C6/36 cells transformed with αDENV -U143-FL, αDENV-ΔU143-ΔN Bax or αDENV -U143-ΔN Bax constructs were challenged with either
one of the four DENV serotypes (MOI 0.1). 1x106 cells were assessed for caspase 3 activity, an indication of apoptosis at 4d.pi (for DENV), and analyzed
for caspase activity in a 96-well microtiter plate format per the manufacturer’s instructions (see Methods). Uninfected clonal and wild type C6/36 cells
were also assayed as an additional negative control. Assays were performed in triplicate. Error bars indicate standard deviation of three independent
experiments. I = infected naïve C6/36 cells. U = uninfected naïve C6/36 cells. ΔU143 = the anti-DENV group I intron (αDENV-ΔU143) possessing the
inactive deletion mutation of the trans-splicing domain.
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Figure 9 DNA Fragmentation Assay: Clonal Aedes albopictus C6/ 36 cells transformed with αDENV -U143-FL, αDENV -ΔU143-ΔN Bax or
αDENV-U143-ΔN Bax were each challenged with one of four known DENV serotypes (MOI 0.1). At 4 dpi (for DENV) cells were pelleted,
lysed, and analyzed as described in Methods. Uninfected clonal and wild type C6/36 cells were also assayed as an additional negative control.
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verified that the insertion of the UAA codon in the P9.0
helix of the group I intron effectively insures no expression
of the ΔN Bax effector gene in the absence of splicing.
Annexin V staining of cloned cells expressing the
αDENV-U143-ΔN Bax linked to a DCV-IRES/mCherry
reporter demonstrated approximately 3 fold activation of
the initial stages of cellular apoptosis over untransformed
control infected cells, and 2 fold greater induction of
apoptosis over infected αDENV-U143-FL expressing cells.
The induction of apoptosis occurred irrespective of the
DENV serotype used as challenge (Figure 8A), with C-11
surprisingly exhibiting similar apoptosis levels compared
to the 11 other cloned cell lines.
As expected, neither wild type C6/36 or C6/36 cells
transformed with a mCherry fluorescence marker dis-
played detectable annexin V-FITC staining (Figure 8A)
comparable to αDENV-U143-ΔN Bax clonal lines fol-
lowing DENV infection. This result was also observed
for cells stably expressing the inactive intron αDENV-
ΔU143-ΔN Bax.
The activation of caspases (cysteinyl aspartate-specific
proteases) is an important marker of the cell’s entry point
into the apoptotic signaling cascade [58,59]. C6/36 cell
clones expressing αDENV-U143-ΔN Bax linked to a
DCV-IRES/mCherry configuration were challenged with
each of the four DENV serotypes (MOI = 0.01) and ana-
lyzed at 4 d.p.i. for the progression of apoptosis bymeasuring caspase 3 activity in 96 well microtiter plates
(Figure 8B) as described in Methods. As a control, C6/36
clonal cell lines stably expressing the αDENV-U143-ΔN
Bax intron were assayed in the absence of virus to verify
that stable expression of the intron itself does not trigger
apoptosis, which again confirmed the effectiveness of the
UAA codon in the P9.0 helix of the group I intron in pre-
venting premature expression of the ΔN Bax effector gene.
Our caspase-3 assays mirrored the annexin V staining
results indicating apoptotic cell death in our DENV in-
fected αDENV-U143-ΔN Bax transformed cell clones.
Caspase-3 activity was detected in all DENV infected
cloned cell populations irrespective of the serotype chal-
lenge, and at levels approximately 10 fold greater than
control infected cells that did not possess an active anti-
DENV intron. Once again, clone C-11 exhibited reduced
caspase activity of approximately two fold greater than
negative control infected cell lines. As expected, con-
trol wild type C6/36, C6/36 cells transformed with the
mCherry fluorescence marker, and cells expressing the in-
active αDENV-ΔU143-ΔN Bax displayed detectable cas-
pase 3 activity following challenge with DENV (Figure 8B).
As a final demonstration of apoptotic activity we
examined the characteristic degradation of nuclear
DNA into nucleosomal units of approximately 180 bp in
length [60]. DNA fragmentation analysis was performed
as previously described [61] on infected αDENV-U143-
ΔN Bax clonal cells infected with each of the four DENV
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Briefly, at 5 d.p.i. cells were lysed, proteinase K and
RNase A treated, and bands separated by electrophoresis
on a 2% gel. As expected, infection of wild type C6/36
cells stably expressing the mCherry fluorescent marker
or αDENV-U143-FL did not result in fragmentation
of nuclear DNA. Similarly, clonal populations stably
expressing αDENV-U143-ΔN Bax did not display observ-
able DNA fragmentation in the absence of DENV infec-
tion, again confirming no premature expression of the ΔN
Bax effector gene. Irrespective of the DENV serotype used,
DNA fragmentation was evident in all αDENV-U143-ΔN
Bax clonal cell populations tested except C-11, mirroring
both TCID50 and Caspase 3 assay results.
Discussion
This study examines the effectiveness of a constitutively
expressed group I intron that targets and trans-splices
conserved sequences and induces apoptotic cell death
upon infection as a means of suppressing DENV virus in-
fection of transformed mosquito cells. Group I trans-spli-
cing introns have established potential for targeting RNA
virus genomes in infected cells [18,32,33]. Previously we
determined an optimal group I intron target sequence fol-
lowing an alignment of 98 instances of DENV that identi-
fied one highly conserved region positioned within the
capsid coding sequence at nucleotides C131 to G151
[38,62]. These nucleotides are a part of the 5’-3’ CS do-
main of the DENV genome [18] that is essential for DENV
replication [62]. We designed an anti-DENV group I
trans-splicing intron, with firefly luciferase serving as the
3’ exon, and demonstrated its ability to effectively cleave
at nucleotide position U143 [18]. We also demonstrated
its ability to effectively trans-splice an infecting DENV-2
NGC when constitutively expressed as RNA in trans-
formed C6/36 cells [18].
In this report we demonstrate the feasibility of using the
U143 targeting group I intron, αDENV-U143, to catalyze
trans-splicing of the 5’ CS region of DENV genomes to a
3’ ΔN Bax exon to induce apoptotic death of cells upon
infection. A UAA stop codon inserted in the trans-splicing
domain of the intron prevents premature expression of
the ΔN Bax 3’ exon that would induce cell death in unin-
fected cells. Upon infection, αDENV-U143-ΔN Bax tar-
geting and cleavage of DENV genomes at uracil 143 forms
a chimeric mRNA that consists of the 5’ cap, 5′ UTR, 143
nucleotides of the DENV capsid (DCA) coding sequence,
and the 3’ ΔN Bax exon. This chimeric RNA is capable of
expressing a DCA-ΔN Bax fusion protein that induces
apoptotic cell death precluding productive virus infection.
The strategy of targeting conserved sequences in the
CS region of the genome cannot be considered immune
to the evolution of escape mutations, but the extreme
conservation of this region among all DENV, and evenamong Flaviviruses, suggests a markedly decreased po-
tential for these mutations to develop. One obvious
drawback to using these catalytic RNA molecules as
simple genome degrading agents is that if the rate of
virus replication exceeds the rate of group I intron cata-
lytic suppression the evolution of escape mutants may
be enhanced. An added level of insurance against the
development of escape mutants should be achieved
through the induction of cellular apoptotic pathways in
response to DENV infection. Coupling the splicing activ-
ity of the group I intron to a death-upon-infection strat-
egy insures that DENV replication rates do not exceed
group I intron expression and catalytic rates, and should
decrease the probability of generating escape mutants.
The use of a group I intron to induce cellular death
upon infection has potential advantages over an RNAi
suppression strategy since the length of conserved
sequence necessary for group I intron targeting can be
discontinuous as well as smaller than that required for
RNAi-mediated responses. While successful RNAi re-
sponses in mosquitoes have been developed to directly
target individual dengue serotype genomes [15,16,63-66],
the RNAi approach may have difficulties targeting all
serotypes simultaneously, and there is the possibility that
escape mutants may amplify without restriction in re-
sponse to the RNAi suppression.
The targeting and cleavage capability of our intron con-
structs was demonstrated with transient transfection as-
says in C6/36 mosquito cells challenged with infectious
DENV. Sequencing analysis confirmed that the correct
splice product was obtained, indicating proper targeting
and site-specific cleavage of the DENV genome by the
transiently expressed αDENV-U143 introns. Addition of
the IRES/mCherry reporter configuration immediately
downstream of the 3’ ΔN Bax exon did not appear to alter
the trans-splicing capabilities of the intron, or affect the
ability of the DCA-ΔN Bax resulting from the splice pro-
duct to initiate apoptosis in DENV infected cells.
Our 5’-RLM-RACE results demonstrate that there is a
56 nt 5’ extension of RNA sequence in our anti-DENV
group I intron resulting from expression by the A5c pro-
moter that does not prohibit targeting and trans-splicing
of DENV genomes (Additional file 1: Figure S1). However,
we cannot rule out the possibility that an enhancement in
anti-DENV group I intron activity could be achieved if the
56nt 5’ extension could be eliminated. This does not
appear to be possible at this time since all RNA pol II pro-
moters add a 5’ extension of considerable length due to
the placement of their respective TSS, and elimination of
this sequence typically results in greatly diminished RNA
pol II promoter activity [67].
Expression and pro-apoptotic function of ΔN Bax is
not inhibited by the 19 amino acids of the Dengue CA
protein fused to its N-terminus. Expression and activity
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nificantly different, and trans-splicing of the DENV
RNA genome by αDENV-U143-ΔN Bax leads to the
activation of cellular apoptosis as indicated by annexin
V-FITC (Figure 8A), caspase 3 assays (Figure 8B), and
DNA ladder analysis (Figure 9 and Additional file 3:
Figure S3).
In regards to the difference between Annexin V and
Caspase-3 assays with reference to the C-11 cell clone,
several labs have successfully demonstrated that the early
stages of apoptosis can be reversed [68-72]. The ability of
U143-ΔN Bax mRNA to translocate out of the nucleus
may be hampered, leading to a decrease in the number of
DCA-ΔN Bax mRNA fusion molecules that are produced
following DENV-U143-ΔN Bax targeting of DENV RNA
in the cytoplasm of C-11 clonal cells. The diminished
protein expression of DCA-ΔN Bax perturbs the progres-
sion of C-11 from the early stages of apoptosis (positive
Annexin V staining) to the latter stages of apoptosis (nega-
tive Caspase 3 activity and DNA fragmentation). None of
these assays indicate apoptotic cell death when the
trans-splicing negative αDENV-ΔU143 or mCherry are
expressed or when FL is used as the 3’ exon, confirming
our results are a consequence of the presence of a
trans-spliced RNA encoding the DCA-ΔN Bax. Other re-
searchers have analyzed N-terminal epitope-tagged va-
riants of tBax with little alteration in activity [40,73,74].
This is likely due to the fact that the C-terminal residues
of Bax possess the pore forming function of this pro-
apoptotic protein.
TCID50-IFA results demonstrate suppression of infec-
tious virus production from our transformed and hygro-
mycin selected cell lines upon challenge with each of the
four serotypes (Figure 6). While we observe as much as
a 5 log decrease in viral titer with each of the four sero-
types targeted, the effector gene is even more potent
than these uncloned, hygromycin-selected transformed
cells demonstrate because these cultures necessarily pro-
duce hygromycin-resistant, non-transformed susceptible
cells. Support for this reasoning is provided by the ob-
servation that removal of hygromycin selection results in
a rapid recovery of virus susceptibility for our trans-
formed cultures.
In contrast, a greater antiviral effect was observed with
transformed clonal cell populations in which every cell is
confirmed to express the αDENV-U143-ΔN Bax intron by
detection of the DCV-IRES expression of the mCherry
marker from the same transcript (Figure 7). The enhanced
DENV suppression observed for αDENV-U143-ΔN Bax
vs. αDENV-U143-FL clones reflects a lack of dependency
upon complete cleavage of all DENV genomes within in-
fected cells expressing αDENV-U143-ΔN Bax due to the
potency of the proapoptotic DCA-ΔN Bax product gene-
rated. Our results validate the utility of this single antiviraleffector gene as a means for producing transgenic mosqui-
toes that will be refractory for DENV transmission.
Recently, a DENV-5 serotype has been identified in
non-human primates from Malaysia that is characterized
by a different antibody profile than the four known DENV
serotypes [75]. This discovery will significantly impact
vaccine development efforts, and may further enhance the
attractiveness of anti-DENV transgenic mosquito strat-
egies that can affect all serotypes. Although no sequence
data is available for DENV-5 at the time of this submis-
sion, there is a high likelihood that the 5’-3’ CS domain
will be conserved in this isolate as well, making it suscep-
tible to our anti-DENV group I intron, U143.
We now have an anti-DENV group I intron that allows
us to target at least four, and likely all five, DENV sero-
types simultaneously. Targeting all serotypes with a sin-
gle catalytic ribozyme or siRNAs eliminates the necessity
to construct and test separate catalytic RNAs or siRNA
molecules. However, unlike siRNA molecules that have
been designed to target conserved regions of DENV in
mammalian cells, the induction of cellular apoptosis by
our αDENV- U143-ΔN Bax construct following DENV
trans-splicing eliminates escape mutants that may evolve
in the infected cell and prevents virus replication from
overriding the catalytic activity of the anti-DENV group
I intron.
These results foreshadow the potential efficacy of our
U143-ΔN Bax constructs against DENV infection of
transgenic mosquitoes expressing these antiviral effectors.
Based on natural infection rates of midgut cells and the
regenerative capabilities of midgut epithelia we do not ex-
pect that the loss of cells upon ingestion of a blood meal
will have a significant impact on the survivability of the
transgenic mosquitoes. This is a potential advantage in the
dissemination of this transgene within the native popula-
tion. Finally, our demonstration that the appended 56 nu-
cleotide 5’ extension resulting from transcription of the
U143 intron does not inhibit targeting or trans-splicing of
the DENV RNA genome suggests to us that an antiviral
group I intron construct capable of targeting multiple vi-
ruses simultaneously should be possible. For us the most
likely virus candidates for such a dual targeting construct
would be DENV and chikungunya viruses since these co-
endemic pathogens have been shown to simultaneously
infect humans and vector mosquitoes [76,77].
Methods
Cells, virus and antibody
Ae. albopictus C6/36 cells were obtained from ATCC, and
maintained in Leibovitz’s L-15 media (Atlanta Biologicals)
supplemented with 10% FBS (Atlanta Biologicals), 10%
TPB (triptose phosphate broth; Invitrogen/Gibco), peni-
cillin G (100 U/ml; Invitrogen/Gibco) and streptomycin
(100 μU/ml; Invitrogen/Gibco). The C6/36 cells used in
Carter et al. Virology Journal 2014, 11:111 Page 14 of 18
http://www.virologyj.com/content/11/1/111this study were maintained in a 28°C incubator and pas-
saged every 4 days. For assays involving DENV infection,
L-15 media supplemented with 2% FBS and 10% TPB
were used. Viral stocks were prepared as previously de-
scribed [17].
DENV sequence data for the four serotypes used in
this study were obtained from NCBI, and comprise the
following Genbank GenInfo identifiers: DENV type 1
Hawaii: DQ672564.1, DENV type 2 strain New Guinea
C (NGC): AF038403.1, DENV type 3 strain ThD3 0010
87(strain H87): AY676352.1, DENV 4 strain DENV-4/
SG/06K2270DK1/2005 (strain H241): GQ398256.1.
Plasmid construction
The identity and integrity of all plasmids used were
assured through sequencing and restriction analysis. All
restriction enzymes were obtained from New England
Bio Labs (NEB). See Additional file 4: Table S1 for se-
quences of all primers used.
Expression plasmids for analysis of ΔN Bax fusion pro-
tein activity were constructed from the D. melanogaster
MT inducible promoter vector, pMT-V5-HisA (Invitrogen).
Individual plasmids containing insertions of PCR EGFP
(pMT-EGFP), full length Bax (pMT-Bax) transcript variant
alpha (GenBank accession: NM-138761), or ΔN Bax ORF
(pMT-ΔN Bax) were constructed by insertion of synthe-
sized sequences (Bio Basic, Inc.) into EcoRI/NotI digested
pMT-V5-HisA. Plasmid pMT-DCA was constructed by
inserting the 5’ terminal fragment of the DENV-2 genome
PCR amplified from pRS424-DENV-2 NGC [78] into the
EcoRI/XhoI digested pMT-V5-HisA plasmid (Additional
file 4: Table S1). The pMT-DCA-ΔN Bax fusion plasmid
was constructed by insertion of the ΔN Bax sequence into
the XhoI/MluI digested pMT-DCA vector.
The Drosophila melanogaster actin 5c (A5c) promoted
U143 trans-splicing intron employed in this study was
used previously to trans-splice DENV type 2-NGC tar-
gets to the firefly luciferase (FL) as the 3’ exon [18]. Our
negative control for trans-splicing activity, ΔU143, was
produced by removing the entire catalytic core [43], do-
mains P4 through P6 of the U143 by PCR amplification
with Platinum Taq polymerase (Invitrogen) using the
forward and reverse primers listed in Additional file 4:
Table S1 (pA5c-Δ U143-ΔN Bax). The PCR product was
used to replace the catalytic core of the group I intron
in U143 using the enzymes MluI and XhoI resulting in a
control intron that lacked trans-splicing activity.
Anti-DENV group I introns U143 and ΔU143 con-
structs possessing the apoptotic ΔN Bax 3’ exon were
assembled by insertion of a PCR amplified 243 nucleo-
tide ΔN Bax gene (Additional file 1: Table S1; ΔN Bax)
into the XhoI/NotI cleaved pA5c-U143-FL plasmid [18],
replacing the FL 3’ exon to yield pA5c-ΔU143-ΔN Bax.
Production of anti-DENV group I intron constructspossessing the DCV intergenic IRES site driving an
mCherry fluorescent marker was achieved by subcloning
DCV-mCherry from the corresponding U143-FL con-
struct into pA5c U143-ΔN Bax using XbaI and SacI re-
striction sites ([18]; Figure 2).
The cDNA plasmids encoding the predicted DENV-ΔN
Bax trans-spliced products for 4 DENV serotypes were pre-
pared by RT-PCR amplification of the DENV 5’ UTRs from
each virus with MluI and XhoI tailed primers (Additional
file 4: Table S1). The resulting PCR fragments were digested
and ligated into pA5c- U143-ΔN Bax in place of the U143.
These constructs are named pA5c-DENV1-ΔN Bax + ctrl,
pA5c-DENV2-ΔN Bax + ctrl, pA5c-DENV3-ΔN Bax +
ctrl, and pA5c-DENV4-ΔN Bax + ctrl (Additional file 4:
Table S1).
Reverse transcription-PCR of DENV-ΔN Bax splice
products derived from cell culture
Extraction of RNA from DENV infected and uninfected
cells were performed using the Qiashredder and RNeasy
Mini kits (QIAGEN Inc., Valencia, CA, USA). Extracted
RNA (5ug) was DNase treated using Turbo DNA-free
DNase (Applied Biosystems/Ambion, Inc. Austin, TX
USA). RT-PCR was performed using the SuperScript III
One-Step RT-PCR kit (Invitrogen) [18] except the PCR
reaction was carried out for 50 cycles. Plasmids expres-
sing each serotype-specific DENV-ΔN Bax splice pro-
duct were used as an RT-PCR size control.
RT-PCR for the presence of DENV
This assay was performed as described above for the
analysis of trans-spliced products except DENV virions
were extracted from C6/36 cell supernatants (500μl) by
Trizol extraction. DNase I treated RNAs were amplified
using the Access Quick RT-PCR kit (Promega). Follo-
wing cDNA synthesis the PCR amplification was carried
out for 25 cycles with primers to DENV-2 E.
5’-RLM-RACE (RNA ligase mediated-rapid amplification of
cDNA ends)
This assay was performed as described by the manufac-
turer (Invitrogen). Briefly, following extraction from cells,
5 μg of total RNA was dephosphorylated with Antarctic
phosphatase (New England Biolabs) to eliminate the 5’
phosphates from truncated mRNA and non-mRNA. After
phenol/chloroform extraction, the 5’-Cap structure is re-
moved from the dephosphorylated mRNA present in the
sample with tobacco acid pyrophosphatase (TAP) which is
required for ligation to the 5’ Oligo specific primer (see
Additional file 4: Table S1). Following another round of
phenol/chloroform extraction, the 5’ primer was ligated to
the 5’ end of the full-length, decapped mRNA using T4
RNA ligase. RT-PCR was then performed as described
above using a forward primer specific to the ligated Oligo-
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primer that binds to the trans-splicing domain of the
group I intron (U143 Rev, Additional file 4: Table S1).
Amplified DNA was resolve on a 2% agarose gel. A 250bp
band, the predicted size of the TSS-containing tran-
script, was extracted using the Wizard SV gel extraction
kit (Promega), and TOPO-TA cloned (Invitrogen) for
sequencing.
Western blot analysis for ΔN Bax induction
C6/36 cells were transfected with 0.2 ug of pMT-EYFP as
a transfection and induction marker and 1g of either
pMT-DCA as a negative control for apoptosis, pMT-ΔN
Bax, pMT-DCA-ΔN Bax, pMT-FMDV2A-ΔN Bax using
Cellfectin transfection reagent (Invitrogen) per the manu-
facturers protocol. At 48 hours post-induction with cop-
per sulfate, the cells were scraped from the bottom of the
well and the entire suspension, including detached cells,
was centrifuged at 1000XG for 10 minutes. For whole cell
lysates, cell pellets were resuspended with Laemmli buffer
containing the following protease and phosphatase in-
hibitors: 10mM benzamidine, 10 mM sodium fluoride,
100mM sodium vanadatephenylmethanesulphonylfluoride
(1mM) (PMSF), 25 μg/mL leupeptin, 25 μg/mL aprotinin,
and 25 μg/mL pepstatin. Whole cell lysates were soni-
cated, and protein concentrations were determined by op-
tical density spectrophotometry at 280 nm on a Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies
Inc., Wilmington, DE) and an equal amount of each
protein sample was loaded in each well. Whole cell ly-
sates were separated via 10% SDS-PAGE, transferred to
nitrocellulose filters, blocked in 5% skim milk in PBS, and
incubated overnight with mouse monoclonal anti-Bax
antibody, sensitive to the extreme C-terminus of ΔN Bax,
(BD Biosciences Pharmagen, San Jose, CA) at a concen-
tration of 1:150. Anti-mouse HRP conjugated secondary
antibody (Amersham Biosciences, Piscataway, NJ) was in-
cubated with the filter at concentration of 1:5000 for 1
hour. Actin was visualized using a goat polyclonal anti-
actin (Santa Cruz Biotechnology, Santa Cruz, CA) at a
concentration of 1:100. Anti-goat HRP conjugated secon-
dary antibody (Santa Cruz Biotechnology) was incubated
with the filter at concentration of 1:5000 for 1 hour. Spe-
cific bands were detected via chemiluminescence (Super-
Signal West Dura, Pierce, Rockford, IL) and exposure to
x-ray film. Films were scanned with a flatbed computer
scanner.
Amido black assay
The amido black assay was performed as previously de-
scribed [50]. Triplicate wells of C6/36 cells were co-
transfected with 0.3 μg of pMT-EYFP as a transfection
marker and 0.6 μg of either pMT-DCA, pMT-ΔN Bax,
pMT-FMDV2A-ΔN Bax or pMT-DCA-ΔN Bax, andanalysis was performed at 6, 24, and 48 hours following
CuSO4 induction. Cells were washed twice with 1× PBS
(pH7.4), and fixed in 4% gluteraldehyde (Fisher Scientific)
for 15 minutes. The gluteraldehyde was aspirated and 1ml
of 0.1% amido black staining solution was added [0.1 gram
amido black 10B (C.I. 20470, Sigma-Aldrich), 7.5ml glacial
acetic acid (Fisher Scientific), 20 ml 100% ethanol
(Pharmco-Aaper, Shelbyville, KY), in 100ml with deio-
nized water]. The plate was gently rocked for 30 minutes,
each well washed twice with 1 ml 0.1 M acetate (pH4.5),
and eluted with 1 ml 50 mM NaOH. Optical absorbency
was read on a Nanodrop ND-1000 spectrophotometer at
620 nm and at 405 nm. The value obtained at 405 nm was
subtracted from that obtained at 620 nm for the reading
[50]. The value recorded for the pMT-DCA well, the
apoptosis negative control, was set to 100% and all other
readings adjusted by the same ratio to obtain a normalized
reading. Data was analyzed using an ANOVA test with a
Tukey’s post-test to compare all data sets within each time
point for significance.Cytopathic effect (CPE) assay
This assay was performed as previously described [17].
Briefly, αDENV-U143-ΔN Bax transformed C6/36 cells
were seeded at a density of 6 × 104 cells/cm2 in T-25 flasks
and incubated overnight at 28°C to allow attachment.
Once attached cells were washed twice with plain L-15
media, and infected with the DENV serotype indicated
(Figure. 5; 0.1 MOI). Micrographs were taken at 6 dpi with
a Nikon E-600 inverted phase light microscope fitted with
a Nikon DS Camera system at 20× magnification.Annexin V
Binding of annexin V to translocate the phospholipid
phosphotidylserine (PS) allows for the detection and
analysis of apoptotic cells [51,56,57]. These assays were
performed using the Annexin V FITC Assay Kit as indi-
cated by the manufacturer (Cayman Chemical Co.) with
a few modifications. Briefly, C6/36 clonal cell lines stably
expressing αDENV-U143-FL, αDENV-ΔU143-ΔN Bax
or αDENV-U143-ΔN Bax ΔN Bax and wild type
C6/36 cells were infected with each DENV serotype
(MOI = 0.1). At 48 hpi 1 × 106 clonal cells were scraped
and placed in a well of a 96 well black opaque microtiter
plate in triplicate for each clonal cell type assayed.
FITC-annexin V microtiter plates were assayed for
FITC-annexin V binding at 485 nm with the Spectra
max M2 luminometer (Molecular Devices) and analyzed
with Softmax Pro 5.4.5. Uninfected clonal and wild type
C6/36 cells were also assayed as an additional nega-
tive control. Assays were performed in triplicate. Error
bars indicate standard deviation of three independent
experiments.
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Further validation of apoptosis induction was performed
by assaying for increases in caspase-3 and other DEVD-
specific protease activities using the EnzChekCaspase-3
Assay Kit #2 Kit (Life Technologies) as directed by the
manufacturer. Briefly, C6/36 clonal cell lines stably ex-
pressing αDENV-U143-FL, αDENV-ΔU143-ΔN Bax or
αDENV-U143-ΔN Bax and wild type C6/36 cells were
infected with each DENV serotype (MOI = 0.1) and
assayed for caspase 3 activity at 4 d.pi. 1×106 clonal cells
were lysed, cell debris was pelleted, and lysates were
placed in a well of a 96 well black opaque microtiter
plate in triplicate for each clonal cell type assayed. Fol-
lowing addition of the Z-DEVD–R110 substrate, micro-
titer plates were assayed for Caspase activity at 496 nm
with the Spectra max M2 luminometer (Molecular De-
vices) and analyzed with Softmax Pro 5.4.5. Uninfected
clonal and wild type C6/36 cells were also assayed as an
additional negative control. Assays were performed in
triplicate. Error bars indicate standard deviation of three
independent experiments.
DNA fragmentation assay
Clonal C6/36 cells stably expressing αDENV-U143-FL,
αDENV-ΔU143-ΔN Bax or αDENV-U143-ΔN Bax and
wild type C6/36 cells constructs were infected with one of
four known DENV serotypes (MOI = 0.1) and assayed for
DNA fragmentation as previously described [61]. Briefly,
at 4 dpi cells were scraped, pelleted and lysed overnight at
50°C in lysis buffer [1.67 mg/ml Proteinase K, 10mM Tris
(pH8.0), 100mM NaCl, 0.5% SDS 25mM EDTA]. Genomic
DNA was extracted with 200 μl Phenol:Chloroform:IAA
(25:24:1) and sodium acetate/ethanol precipitated. DNA
pellets were resuspended in 20 μl TE buffer, RNase A
treated (6.0 mg/ml) at 37°C for 3 hours, analyzed by 2%
agarose gel electrophoresis at 5 v/cm and visualized under
UV light. DNA fragmentation is demonstrated by the
appearance of a DNA ladder-like pattern. Uninfected
clonal and wild type C6/36 cells were also assayed as an
additional negative control.
TCID50-IFA analysis of dengue viruses
We used immunofluorescence detection of cell surface
expressed DENV E protein in C6/36 cultures infected with
serial 10 fold dilutions to assess DENV titer for all 4 sero-
types as previously described [17]. 10 fold serial dilutions
of infected C6/36 cell culture supernatants were harvested
at 48 hpi and used as inoculum for 96 well plate cultures
of naïve C6/36 cells. Plates were incubated for 4 days at
28°C without CO2, washed, fixed with acetone:DPBS (3:1),
and stained with a primary DENV envelope (E) antibody
(1:200) [79], followed by a biotinylated-streptavidin detec-
tion system conjugated with FITC (Amersham Biosciences,
Piscataway, NJ). Wells displaying cellular fluorescence werescored as positive for DENV infection. The number of
positive wells were counted and the virus titers calculated
according to Karber’s method [80]. The deletion mutation
of the trans-splicing domain (αDENV -ΔU143) is designed
to knock out trans-splicing function, providing a negative
control [81]. TCID50-IFA analysis of clonal cell populations
expressing αDENV -U143-FL or αDENV -U143-ΔN Bax
constructs was performed in this manner.Establishment of clonal cell populations
Clonal cell populations were produced as previously
described [65]. Briefly, C6/36 cells stably expres-
sing αDENV -U143-FL, αDENV -ΔU143-ΔN Bax or
αDENV -U143-ΔN Bax were grown to 4 × 102 cells/cm2
and then diluted to 0.2 cells/cm2. 100ul of this cell suspen-
sion was placed in each of a 96 well plate and grown to
confluency. Twelve wells of each plate were scraped and
transferred to individual wells of a 24 well plate. Once
confluent, cells were then transferred to a 12 well plate,
then a 6 well plate, and lastly T-25 flasks. At each transfer
step cells were maintained with 1mL L-15 complete media
supplemented with 100ug/mL hygromycin. In order to
guarantee clonability 3 cloning cycles were carried out.Additional files
Additional file 1: Figure S1. 5’ RACE transcription start site (TSS)
analysis. A. The predicted sequences of the Actin 5c promoter with the
putative TSS [82] and αDENV-U143 as transcribed in the cell. The adenine
depicting the end of the putative TSS is green, and the 3’ end of the
promoter is red. The IGS and EGS located 6 nucleotides downstream of the
3’ end of the A5c promoter are labeled and underlined. Nucleic acids are
numbered in relation to their position downstream from the TSS (+1).
B. RT-PCR products were resolved by 2% agarose gel electrophoresis as
described in Methods. The RACE product amplified from αDENV-U143-ΔN
Bax was approximately 250 bp as indicated by the asterisk. L = standard
ladder. C. Alignment resulting from sequencing eleven isolates following
TOPO cloning of the 250 bp fragment displayed in Additional file 1:
Figure S1B. The putative TSS and actual TSS of each colony isolate of 11 are
aligned. Complete homology is shown in yellow, partial consensus in blue.
Additional file 2: Figure S2. Clonal cell populations (labeled C-1
through C-11) were challenged with DENV-2 NGC (MOI = 0.01). At 4 dpi
cell supernatants were collected and saved for RT-PCR analysis (see 8b).
Following DENV-2 E protein antigen staining with antibody, micrographs
were taken using the A1-R confocal microscope (Nikon). I = infected,
U = uninfected.
Additional file 3: Figure S3. Clonal cell populations stably expressing
αDENV -U143-FL, αDENV -ΔU143-ΔN Bax or αDENV-U143-ΔN Bax (labeled
C-1 through C-11) were challenged with DENV-1, DENV-2 (see Figure 9)
DENV-3, or DENV-4 (MOI = 0.1). At 4dpi analysis of DNA fragmentation
was performed as described in Methods. I = infected, U = uninfected.
Additional file 4: Table S1. Primers used for plasmid construction and
5’ RLM-RACE. Listed are the forward and reverse primer sets used to
produce the PCR fragments and 5’RLM-RACE analysis. Lowercase nucleic
acids indicate restriction site. See Methods for description of vector
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